Meeting
2020 ASCO Virtual Scientific Program
INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
Authors
Enrique Grande
MD Anderson Cancer Center Madrid, Madrid, Spain
Enrique Grande , Teresa Alonso Gordoa , Oscar Reig Torras , Emilio Esteban , Daniel Castellano , Xavier Garcia del Muro , María José Mendez Vidal , Jesús García-Donas , Jose Angel Arranz , Cristina Suarez Rodriguez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03066427
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5060)
DOI
10.1200/JCO.2020.38.15_suppl.5060
Abstract #
5060
Poster Bd #
129
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.
First Author: Patrick Joseph O'Shea
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2023 ASCO Annual Meeting
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
First Author: Aaron Scott Mansfield